NantHealth Inc (NASDAQ:NH) COO Ronald Allen Louks sold 7,005 shares of the firm’s stock in a transaction dated Friday, April 6th. The shares were sold at an average price of $3.04, for a total value of $21,295.20. Following the sale, the chief operating officer now owns 89,690 shares in the company, valued at approximately $272,657.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Ronald Allen Louks also recently made the following trade(s):
- On Tuesday, March 6th, Ronald Allen Louks sold 7,095 shares of NantHealth stock. The stock was sold at an average price of $3.56, for a total value of $25,258.20.
- On Tuesday, February 6th, Ronald Allen Louks sold 6,475 shares of NantHealth stock. The stock was sold at an average price of $3.02, for a total value of $19,554.50.
Shares of NASDAQ NH opened at $3.26 on Wednesday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 2.26 and a current ratio of 2.28. NantHealth Inc has a 12-month low of $2.60 and a 12-month high of $5.26.
NantHealth (NASDAQ:NH) last issued its quarterly earnings results on Wednesday, March 14th. The company reported ($0.21) EPS for the quarter. The firm had revenue of $22.30 million for the quarter, compared to the consensus estimate of $23.50 million. NantHealth had a negative net margin of 188.81% and a negative return on equity of 54.16%. equities analysts expect that NantHealth Inc will post -0.61 earnings per share for the current year.
Hedge funds have recently modified their holdings of the business. Advisor Group Inc. bought a new position in shares of NantHealth during the fourth quarter valued at approximately $450,000. Millennium Management LLC bought a new position in shares of NantHealth during the fourth quarter valued at approximately $344,000. Dimensional Fund Advisors LP bought a new position in shares of NantHealth during the third quarter valued at approximately $365,000. Northern Trust Corp boosted its stake in shares of NantHealth by 133.9% during the second quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock valued at $643,000 after purchasing an additional 86,955 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of NantHealth by 20.2% during the second quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock valued at $1,792,000 after purchasing an additional 71,087 shares in the last quarter. Institutional investors and hedge funds own 6.25% of the company’s stock.
Several analysts have commented on the stock. BidaskClub upgraded shares of NantHealth from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. Jefferies Group set a $5.00 price objective on shares of NantHealth and gave the stock a “buy” rating in a report on Wednesday, March 21st. Zacks Investment Research upgraded shares of NantHealth from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Thursday, January 11th. Finally, Cowen restated a “buy” rating and issued a $4.50 price objective on shares of NantHealth in a report on Tuesday, March 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. NantHealth has an average rating of “Buy” and a consensus target price of $4.69.
COPYRIGHT VIOLATION WARNING: “Insider Selling: NantHealth Inc (NH) COO Sells 7,005 Shares of Stock” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/04/18/nanthealth-inc-nh-coo-ronald-allen-louks-sells-7005-shares.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.